BioStock: Aptahem comments on the new Covid-19 project
Last night, Malmö-based Aptahem announced that they have entered a preclinical collaboration with the University Health Network in Toronto. The collaboration will be anchored in Aptahem’s previously indicative positive preclinical data, and the objective is to evaluate whether the company’s drug candidate Apta-1 can show a positive treatment effect on the Acute Respiratory Distress Syndrome that can affect severe cases of Covid-19. BioStock contacted Aptahem’s CSO Dr Luiza Jedlina for a comment.
Read the full interview at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se